Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients
2008

Nestin and CD133 as markers for glioma outcomes

Sample size: 125 publication Evidence: moderate

Author Information

Author(s): Zhang Mingyu, Song Tao, Yang Liang, Chen Ruokun, Wu Lei, Yang Zhuanyi, Fang Jiasheng

Primary Institution: The Neurosurgery Department of Xiangya Hospital of Central South University

Hypothesis

The study investigates the correlation of Nestin and CD133 expression with glioma grading and their prognostic value.

Conclusion

Nestin and CD133 expression may indicate the aggressive nature of gliomas and help predict patient outcomes.

Supporting Evidence

  • Nestin and CD133 expression levels were significantly higher in gliomas compared to normal brain tissues.
  • Higher expression of Nestin and CD133 correlated with higher glioma grades.
  • Patients with low expression of these markers had longer survival rates.

Takeaway

This study found that certain markers in brain tumors can help doctors understand how serious the tumors are and how patients might do.

Methodology

The study analyzed tissue samples from glioma patients using immunohistochemical staining to assess Nestin and CD133 expression.

Participant Demographics

85 males and 40 females, mean age 48.13 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-9966-27-85

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication